| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/27/2006 | US20060165592 Nk cell receptor conjugates for treating malignancies |
| 07/27/2006 | DE102005002353A1 Use of receptor multimerization epitope (RME) of advanced glycation end product receptor (AGER) as immunogen, useful for preparing antibodies for diagnosis and treatment of e.g. spinal injuries or diabetic complications |
| 07/27/2006 | CA2595902A1 Binding compounds, immunogenic compounds and peptidomimetics of the beta-3 hairpin loop of cystine-knot growth factors |
| 07/27/2006 | CA2595629A1 Vaccines based on the use of mva |
| 07/27/2006 | CA2595534A1 Improved vaccine against feline calicivirus |
| 07/27/2006 | CA2595333A1 Method of producing conjugate vaccines |
| 07/27/2006 | CA2595163A1 Yersinia spp. polypeptides and methods of use |
| 07/27/2006 | CA2595074A1 Mycobacteria with mannose cap-deficient lipoarabinomannan |
| 07/27/2006 | CA2595063A1 Emulsified composition for dilution and cancer vaccine composition |
| 07/27/2006 | CA2595024A1 Methods for the production of ansamitocins |
| 07/27/2006 | CA2594612A1 Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response |
| 07/27/2006 | CA2594477A1 Pharmaceutical compounds |
| 07/27/2006 | CA2594474A1 Pharmaceutical compounds |
| 07/27/2006 | CA2593561A1 Combining therapies targeting multiple toll-like receptors and use thereof |
| 07/27/2006 | CA2593265A1 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 07/27/2006 | CA2592627A1 Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide |
| 07/27/2006 | CA2592177A1 Fixed dosing of her antibodies |
| 07/27/2006 | CA2575548A1 Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
| 07/27/2006 | CA2567446A1 Alphavirus vectors for respiratory pathogen vaccines |
| 07/27/2006 | CA2563538A1 Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations |
| 07/26/2006 | EP1683870A1 Vaccines based on the use of MVA |
| 07/26/2006 | EP1683867A1 Groups of Borrelia burgdorferi and Borrelia afzelii that cause lyme disease in humans |
| 07/26/2006 | EP1683858A2 Viral preparations, vectors, immunogens, and vaccines |
| 07/26/2006 | EP1683811A2 Compositions and methods for the treatment of tumors |
| 07/26/2006 | EP1683809A1 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 07/26/2006 | EP1683807A1 Combination products for use in antitumoral treatment, comprising an antibody capable of inhibiting the activity of CSF-1 |
| 07/26/2006 | EP1682666A1 Hiv pharmaccines |
| 07/26/2006 | EP1682580A2 Human monoclonal antibody having fat-reducing effect |
| 07/26/2006 | EP1682579A1 Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| 07/26/2006 | EP1682578A1 Peptide-based immunization therapy for treatment of atherosclerosis |
| 07/26/2006 | EP1682575A1 Igf-i responsive gene and use thereof |
| 07/26/2006 | EP1682574A2 The use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases |
| 07/26/2006 | EP1682573A2 The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases |
| 07/26/2006 | EP1682180A2 Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| 07/26/2006 | EP1682179A2 Enhanced b cell cytotoxicity of cdim binding antibody |
| 07/26/2006 | EP1682178A2 Methods of therapy for cancers expressing the cd40 antigen |
| 07/26/2006 | EP1682177A2 Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
| 07/26/2006 | EP1682176A1 Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer |
| 07/26/2006 | EP1682175A2 Improvements in vaccination |
| 07/26/2006 | EP1682174A2 Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same |
| 07/26/2006 | EP1682173A2 Listeria-based epha2 vaccines |
| 07/26/2006 | EP1682172A2 Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis |
| 07/26/2006 | EP1682171A2 Compositions and methods of treating neurological diseases |
| 07/26/2006 | EP1682170A2 Compositions able to prevent neurodegenerative processes and methods of assaying the same |
| 07/26/2006 | EP1682169A1 Compositions and methods of treatment |
| 07/26/2006 | EP1682163A1 Proteins involved in quorum sensing |
| 07/26/2006 | EP1682159A1 Immunomodulating compositions and uses therefor |
| 07/26/2006 | EP1682106A2 Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes |
| 07/26/2006 | EP1390543B1 New polynucleotides and polypeptides of the ifnalpha-17 gene |
| 07/26/2006 | EP1353687B1 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof |
| 07/26/2006 | EP1311297B1 A method for reducing stress-induced overproduction of neuropeptide y in an individual |
| 07/26/2006 | EP1263784B1 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes |
| 07/26/2006 | EP1257297B1 Compositions and methods for treatemnt of angiogenesis in pathological lesions |
| 07/26/2006 | EP1240313B1 Homologue enzymes of human heparanase and splice variants thereof |
| 07/26/2006 | EP1072273B1 Vascularization inhibitors |
| 07/26/2006 | EP1028743B1 TREATMENT AND DIAGNOSIS OF INFERTILITY USING TGF-beta OR ACTIVIN |
| 07/26/2006 | EP0967991B1 Infectious bursitis vaccine |
| 07/26/2006 | EP0904100B1 Cationic lipid and receptor ligand-facilitated delivery of biologically active molecules |
| 07/26/2006 | EP0856058B1 Cell-cycle checkpoint genes |
| 07/26/2006 | EP0758396B1 Feline immunodeficiency virus vaccine |
| 07/26/2006 | CN1809750A Acetyl-coenzyme A carboxylase 2 as a target in the regulation of fat and insulin action |
| 07/26/2006 | CN1809633A Recombinant influenza viruses holding a mutation in a transmembrane protein gene |
| 07/26/2006 | CN1809592A Recombinant antibodies and fragments recognising ganglioside N-glycolyl-GM3 and use thereof in the diagnosis and treatment of tumours |
| 07/26/2006 | CN1809589A GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
| 07/26/2006 | CN1809584A Compositions comprising cationic microparticles and HCV E1E2 DNA and methods of use thereof |
| 07/26/2006 | CN1809383A Recombinant IL-9 antibodies and uses thereof |
| 07/26/2006 | CN1809382A A method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists |
| 07/26/2006 | CN1809381A HIV-1 envelope glycoproteins having unusual disulfide structure |
| 07/26/2006 | CN1809380A Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
| 07/26/2006 | CN1809379A Disease prevention and vaccination prior to thymic reactivations |
| 07/26/2006 | CN1809374A Proton-sensing G-protein coupled receptors and DNA sequences thereof |
| 07/26/2006 | CN1809371A Lyase treatment for p. carinii |
| 07/26/2006 | CN1809370A Use of B7-H3 as an immunoregulatory agent |
| 07/26/2006 | CN1807632A Japan blood fluke Chinese mainland strain SJCXWL06 gene and uses |
| 07/26/2006 | CN1807602A Preparation method of recombinant baculoviral for constructing fowl vaccine |
| 07/26/2006 | CN1807599A Method for safe continuous enclosed cell culture, virus production/ inactivation |
| 07/26/2006 | CN1807455A Breast cancer related gene DREE, its coded protein and uses |
| 07/26/2006 | CN1807450A SIP gene and its coded protein and uses |
| 07/26/2006 | CN1806849A Method of treating tumors |
| 07/26/2006 | CN1806848A Novel use of thymosin alpha protogene |
| 07/26/2006 | CN1266162C Nucleotide specific to shigella bodyii 10 O-antigen |
| 07/26/2006 | CN1265841C Swing breeding and respiratory syndrome suicide DNA vaccine and use |
| 07/26/2006 | CN1265712C Improved anti-inflammatory herbal composition and application method thereof |
| 07/25/2006 | US7081529 Recombinant vaccine against botulinum neurotoxin |
| 07/25/2006 | US7081523 And stimulate erythropoiesis; teatment of anemia |
| 07/25/2006 | US7081518 For the diagnosis and therapy of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin |
| 07/25/2006 | US7081513 Peptides having Chemotaxis Inhibitory Protein from Staphylococcus aureus (CHIPS) activity for diagnosis, prophylaxis and treatment of inflammation and HIV |
| 07/25/2006 | US7081354 Interleukin and albumin fusion protein |
| 07/25/2006 | US7081342 Using attenuated viral sequence to develop vaccines to prevent porcine reproductive and respiratory syndrome in swine; immunotherapy |
| 07/25/2006 | US7081341 A plasmid containing an rRNA gene having a mutant Anti-Shine-Dalgarno sequence, at least one mutation in such rRNA gene, and a genetically engineered gene which encodes a selectable marker having a mutant Shine-Dalgarno sequence |
| 07/25/2006 | US7081245 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 07/25/2006 | US7081244 Genetic engineering; vaccines; induction immunology response, antibodies |
| 07/25/2006 | US7081243 Can be employed to target cells infected with another virus such as HIV |
| 07/25/2006 | US7081242 Administering conjugate comprising (a) a non-immunogenic valency platform molecule and (b) two or more molecules comprising double stranded DNA (dsDNA) epitopes, wherein the dsDNA epitopes are polynucleotides which specifically bind to an antibody from the individual |
| 07/25/2006 | US7081241 Extracellular rage binding protein (EN-RAGE) and uses thereof |
| 07/25/2006 | US7081239 Administering formulation comprising peptide YY or antagonists of receptors for peptide YY for manipulating the rate of upper gastrointestinal transit of a substance in a mammal having an intrinsic cholinergic afferent neural pathway |
| 07/25/2006 | CA2206423C Antithrombotic agent and anti-von willebrand factor monoclonal antibodies |
| 07/20/2006 | WO2006076736A2 Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions |
| 07/20/2006 | WO2006076651A2 Treatment method |
| 07/20/2006 | WO2006076640A1 Monoclonal antibodies that bind or neutralize hepatitis b virus |